BioSpace News Archive

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced publication of a peer-reviewed study in Facial Plastic Surgery & Aesthetic Medicine investigating the safety and utility of the Company’s PURION® processed dHACM (EPIFIX®) for use in Mohs micrographic surgeries (MMS).

BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company, announced today that Company Co-Founder and Chief Medical Officer David Berd, MD, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 taking place November 30-December 2, 2021 in San Diego.

Dermata Therapeutics, Inc. today announced it has enrolled the first patient in its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea.

Aytu BioPharma, Inc. today announced it ranked 178 on the Deloitte Technology Fast 500.

La Jolla Pharmaceutical Company announced that it will commence a share repurchase plan for up to $10 million of the Company’s common stock.

Graphite Bio, Inc. today announced that the first patient has been enrolled in the company’s Phase 1/2 clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).

Boundless Bio to Present at the Piper Sandler 33rd Annual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference.

Abintus Bio, Inc. today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.

DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.